Market Overview

UPDATE: Goldman Sachs Initiates HeartWare International with Neutral

Related HTWR
Contemporary Results From Commercial HVAD System Registries Highlighted At ISHLT Meeting
18 Biotech Stocks These Wall Street Analysts Are Tracking

Goldman Sachs initiated coverage on HeartWare International (NASDAQ: HTWR) with a Neutral rating and a price target of $93.

Goldman Sachs noted, "We initiate on shares of HeartWare (HTWR) with a Neutral rating and 12-month price target of $93, implying 4.1% upside from current levels. Over the long term, the company has the potential to drive accelerating revenue growth for multiple years as the LVAD market continues to develop due to increased utilization and technological advances. That said, HeartWare's entrance into the US market may be more difficult than expected and we see consensus sales estimates as too high. HeartWare, pending approval, will only have access to the slower and more penetrated Bridge-to-Transplant market, making near-term growth almost entirely dependent on shares gains. "

HeartWare International closed at $89.68 on Thursday.

Latest Ratings for HTWR

Aug 2015Credit SuisseAssumesOutperform
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015BarclaysMaintainsOverweight

View More Analyst Ratings for HTWR
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (HTWR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters